null
E-Publication E-Publication

Diagnosis, Imaging, and the Role of Total Kidney Volume in ADPKD


Released:
7/19/19
Expires:
7/18/20

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
7/19/19

Expires:
7/18/20

Maximum Credits:
0.5
E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
7/19/19
Expires:
7/18/20


Maximum Credits:
0.5


Overview: This 30-minute publication provides an overview of the genetics, diagnosis, and screening recommendations of autosomal dominant polycystic kidney disease (ADPKD). The emergence of total kidney volume (TKV) as a prognostic biomarker and the imaging modalities used to measure TKV will also be explored. In addition, it incorporates audio clips of expert faculty providing insights from the perspective of the nephrologist, radiologist, and primary care clinician.

CME Information:

Faculty
Daryl W. Lum, MD
Assistant Professor
Department of Medicine & Health Sciences
Assistant Clinical Professor
General Internal Medicine
David Geffen School of Medicine
University of California Los Angeles Medical Center
Los Angeles, CA
 
Steven S. Raman, MD, FSAR, FSIR
Professor of Radiology, Urology, and Surgery
Director of Abdominal Imaging Fellowship
Department of Radiology
David Geffen School of Medicine
University of California Los Angeles Medical Center
Santa Monica, CA
 
Anjay Rastogi, MD, PhD
Professor and Clinical Chief
Department of Medicine, Division of Nephrology
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, CA

Activity Planners
Susan Kuhn, MHSc
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Writer
Katherine Kahn
Holyoke, MA
 
Learning Objectives
Upon completion, participants should be able to:

  • Summarize the screening/diagnostic recommendations for and clinical manifestations of ADPKD
  • Evaluate the advantages and disadvantages associated with imaging modalities used to obtain TKV measurements

Target Audience
This activity is intended for nephrologists, radiologists, and primary care clinicians. 
 
Statement of Need
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease that affects approximately 12.5 million people worldwide. It is characterized by the development and continued growth of renal cysts that contribute to kidney enlargement, pain, hypertension, decreased quality of life, and the eventual development of end-stage renal disease. Until recently, available treatment strategies only targeted the resulting symptoms of ADPKD but had no effects on slowing disease progression. However, disease-modifying therapies with the potential to delay ADPKD progression have started to emerge with the FDA approval of the first disease-modifying therapy, bringing additional challenges to primary care physicians, nephrologists, and radiologists who identify and manage patients with this condition. Because of these advances, clinicians will benefit from receiving new information on recognizing patients with rapidly progressing disease, incorporating total kidney volume measurements as a prognostic marker into clinical practice, and identifying appropriate management strategies based on the patient’s risk of disease progression.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: July 19, 2019
Expiration Date: July 18, 2020
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

Daryl W. Lum, MD, has indicated no real or apparent conflicts.
 
Steven S. Raman, MD, FSAR, FSIR, has indicated no real or apparent conflicts.
 
Anjay Rastogi, MD, PhD, has indicated no real or apparent conflicts.

Susan Kuhn, MHSc
Spouse: Ownership interest (stocks/stock options – excluding mutual funds): Illumina, Johnson & Johnson, Viking Therapeutics

The writer, peer reviewers, and other activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.       
                      
System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Copyright
© 2019 Med-IQ, Inc.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.